Last $40.67 USD
Change Today +1.46 / 3.72%
Volume 371.2K
AGIO On Other Exchanges
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

agios pharmaceuticals inc (AGIO) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/7/14 - $49.79
52 Week Low
11/18/13 - $15.77
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

agios pharmaceuticals inc (AGIO) Related Bloomberg News

View More Bloomberg News

agios pharmaceuticals inc (AGIO) Related Businessweek News

No Related Businessweek News Found

agios pharmaceuticals inc (AGIO) Details

Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its product candidates include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. The company is also developing AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology. Agios Pharmaceuticals, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

96 Employees
Last Reported Date: 03/18/14
Founded in 2007

agios pharmaceuticals inc (AGIO) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $425.0K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $269.1K
Chief Operating Officer
Total Annual Compensation: $350.0K
Chief Scientific Officer
Total Annual Compensation: $376.0K
Compensation as of Fiscal Year 2013.

agios pharmaceuticals inc (AGIO) Key Developments

Agios Pharmaceuticals, Inc. Announces Initial Phase 1 Data Demonstrating Clinical Activity of Ag-221

Agios Pharmaceuticals, Inc. announced that data from its program AG-221 will be presented at a Clinical Trials Symposium titled 'Novel Immune and Targeted Therapies for Hematological Malignancies and Solid Tumors' at the American Association for Cancer Research (AACR) Annual Meeting 2014. These preliminary data demonstrate the clinical activity, tolerability and unique mechanism of action of AG-221 in patients with advanced hematologic malignancies with an isocitrate dehydrogenase-2 (IDH2) mutation. The preliminary data to be presented by Dr. Stein show that in the first two cohorts of the Phase 1 trial of AG-221, six of seven evaluable patients had objective responses, including three complete remissions (CR) and two complete remissions with incomplete platelet recovery (CRp). AG-221 also substantially lowered plasma levels of the oncometabolite 2-hydroxyglutarate (2HG) with a favorable exposure profile and good tolerability to date. These findings corroborate the use of precision medicine in genetically defined patient populations and demonstrate the potential of targeting cancer metabolism to develop transformative medicines for patients. AG-221 is an orally available, selective, potent inhibitor of the mutated IDH2 protein. As of March 20, 2014, this ongoing Phase 1 dose-escalation study had enrolled 22 patients with acute myeloid leukemia (AML) or myelodysplastic syndrome, all of whose cancers harbored an IDH2 mutation. Patient cohorts received AG-221 administered at 30 mg twice a day, 50 mg twice a day, 75 mg twice a day or 100 mg once a day. In presentation, efficacy data will be presented for patients from the first two cohorts (30 mg and 50 mg twice a day). These cohorts enrolled 10 patients with relapsed or refractory AML whose disease had progressed after or was refractory to between one and four prior therapeutic regimens. Median age of these patients was 62.5 years, and all 10 patients had documented mutations in IDH2. Of these patients, seven were evaluable for efficacy (three patients did not complete a full 28-day cycle of therapy and died due to complications of disease-related infection, all in the first dose cohort). Of the seven evaluable patients, six patients had investigator-assessed objective responses, including three patients who achieved complete remission (CR), two patients who achieved complete remission with incomplete platelet recovery (CRp) and one patient with a partial response (PR). One patient with a CR was removed from the study to undergo a bone marrow transplant; all other responses are ongoing with patients continuing to receive drug. Treatment with AG-221 has been well tolerated to date, with no dose-limiting toxicities reported. Possible drug-related severe adverse events were reported in two patients, including one patient with an abnormally elevated white blood count and one patient with confusion and respiratory failure in the setting of disease-related infection. The mechanism of response is consistent with preclinical studies, including substantial reduction of plasma 2HG levels, as well as evidence of cellular differentiation and normalization of cell counts in the bone marrow and blood. This differentiation effect is distinct from that seen with traditional chemotherapeutics used as standard of care for AML regimens. Preliminary analysis of pharmacokinetics (PK) at the 30 mg and 50 mg dose levels demonstrated excellent oral AG-221 exposure and a mean plasma half-life of greater than 40 hours. Based on this PK profile, AG-221 is now being evaluated on a once-a-day and twice daily schedule in parallel. Dose escalation continues on both schedules, as the maximum tolerated dose has not been achieved.

Agios Pharmaceuticals, Inc. - Special Call

To review the clinical data from the ongoing Phase 1 study of AG-221 presented at the AACR Annual Meeting

Agios Pharmaceuticals, Inc. Announces Enrollment of First Patient in Phase 1 Study of AG-120 in Advanced Hematologic Malignancies with an IDH1 Mutation

Agios Pharmaceuticals, Inc. announced that the first patient has been dosed in a Phase 1 study of AG-120 in patients with advanced hematologic malignancies with an isocitrate dehydrogenase-1 (IDH1) mutation. AG-120 is an orally available, selective, potent inhibitor of the mutated IDH1 protein, making it the first targeted therapeutic candidate to treat patients with cancers that harbor the IDH1 mutation. Groundbreaking research by Agios' scientists established for the first time that the mutated metabolic gene IDH1 has novel enzyme activity consistent with a cancer-causing gene or oncogene. This discovery shows that the mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate (2HG), which may contribute to the formation and malignant progression of many forms of cancer, including hematologic malignancies such as acute myeloid leukemia and solid tumors such as gliomas (the most common type of brain cancer), chondrosarcomas and cholangiocarcinomas.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGIO:US $40.67 USD +1.46

AGIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGIO.
View Industry Companies

Industry Analysis


Industry Average

Valuation AGIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 47.8x
Price/Book 9.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 42.3x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AGIOS PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at